ClinicalTrials.gg
Active, not recruitingNCT05611931XPORT-EC-042Updated Oct 29, 2026

Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

A Phase 3 interventional study of Selinexor and Matching Placebo for selinexor in Endometrial Cancer, sponsored by Karyopharm Therapeutics Inc. Active, not recruiting at 185 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Karyopharm Therapeutics Inc · Phase 3, Interventional, and Treatment

Updated Oct 29, 2026Primary completion moved14 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
257
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 715 studies in Endometrial Neoplasms with a site in United States — 197 open to participants now, 286 under way, 22 of them phase 3. Endometrial Neoplasms · United States.

Enrollment
109th of 591
257 · median 60
Started
2023
with 53 others
Phase 3
39 of 715
12 open now
Primary completion
2026-05
later than 44 of 285 live
Registered
520th of 715
by date

Among the 715 studies in Endometrial Neoplasms with a site in United States, this one is the 109th largest by enrollment of the 591 interventional ones that give a count, is one of 54 that started in 2023, is one of 39 in phase 3, reaches primary completion later than 44 of the 285 other live ones, and was the 520th registered.

Endometrial Neoplasms

1,428 studies on the registry are indexed under Endometrial Neoplasms; 472 are open to participants now.

Browse Endometrial Neoplasms studies →

Open to participants now

197 of the 715 studies in Endometrial Neoplasms with a site in United States are open now. Recruiting first, the newest first:

192 more — sign in →

All 197 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 715 studies in Endometrial Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of selinexor as a maintenance treatment in patients with p53 wt endometrial carcinoma (EC), who have achieved a partial response (PR) or complete response (CR) (per Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST v 1.1]) after completing at least 12 weeks of platinum-based therapy. A total of 276 participants will be enrolled in the study and randomized in a 1:1 ratio to maintenance therapy with either selinexor or placebo.

03

Conditions studied

  • Endometrial Cancer

Keywords

  • Selinexor
  • KPT-330
  • Advanced or Recurrent Endometrial Carcinoma
  • XPORT-EC
  • ENGOT-EN20
  • GOG-3083
  • XPORT-EC-042
  • p53 wild-type
  • Tumor protein 53 wild-type
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: Patients must meet all of the following inclusion criteria in order to be eligible to participate in this study:

  • Adults (Aged ≥ 18 years)
  • confirmed endometrial cancer (endometrioid, serous, undifferentiated, or carcinosarcoma sub-types) that is TP53 wild type by central NGS
  • Must have completed at least 12 weeks of platinum-based chemotherapy (with or without ), with a confirmed partial or complete response according to v1.1
  • Must be able to initiate C1D1 within 3-8 weeks after last platinum dose
  • (ECOG) performance status of 0 or 1
  • Adequate bone marrow function and organ function

Exclusion Criteria: Patients meeting any of the following exclusion criteria are not eligible to participate in this study:

  • Uterine sarcomas, clear cell or small cell carcinoma with neuroendocrine differentiation
  • Palliative radiotherapy administered within 14 days of intended C1D1
  • Any gastrointestinal dysfunction that could interfere with the absorption of oral study therapy
  • Serious psychiatric or medical conditions that could interfere with study participation or would make study involvement unreasonably hazardous
  • Previous treatment with an XPO1 inhibitor
  • Stable disease or disease progression after platinum-based chemotherapy
  • Pregnancy, breastfeeding, or other legal/ethical restrictions to trial participation
  • Known dMMR/MSI-H EC tumors that are medically eligible to receive an immune checkpoint inhibitor
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
257 participants (actual)

Study arms

  • Experimental
    Selinexor

    Participants will receive a fixed dose of selinexor 60 milligrams (mg) oral tablets once weekly (QW) on Days 1, 8, 15, and 22 of each 28-day cycle.

    Drug: Selinexor

  • Placebo comparator
    Placebo

    Participants will receive matching placebo for selinexor oral tablets QW on Days 1, 8, 15, and 22 of each 28-day cycle.

    Drug: Matching Placebo for selinexor

Interventions

  • Dose: 60 mg (3 tablets); Dosage form: film-coated, immediate-release tablet of 20 mg each; Route of administration: oral

    Also known as: KPT-330

  • DrugMatching Placebo for selinexor

    Dose:60 mg (3 tablets); Dosage form: film-coated, immediate-release tablet of 20 mg each; Route of administration: oral

06

What researchers measure

Primary outcomes

  1. Investigator assessed Progression Free Survival (PFS) per RECIST v1.1

    Time frame: From randomization until disease progression (PD) or death, whichever occurs first (up to 34 months)

Secondary outcomes

  1. Overall Survival (OS)

    Time from randomization to death due to any cause

    Time frame: Up to 34 months

  2. Safety and tolerability of study drug (selinexor and placebo)

    The safety and tolerability of study drug (selinexor and placebo) will be evaluated based on adverse event (AE) reports, physical examination results (including vital signs), and clinical laboratory results, by means of the occurrence, nature, and severity of AEs via Common Terminology Criteria for Adverse Events (CTCAE) v. 5.0.

    Time frame: From start of study drug administration up to 34 months

  3. Time to First Subsequent Therapy (TFST)

    Time from randomization until date of initiation of first therapy after discontinuation of study drug or death, whichever occurs first

    Time frame: From randomization until date of initiation of first therapy after discontinuation of study drug or death, whichever occurs first (up to 34 months)

  4. Time to Second Subsequent Therapy (TSST)

    Time from randomization until date of initiation of second therapy after discontinuation of study drug or death, whichever occurs first

    Time frame: From randomization until date of initiation of second therapy after discontinuation of study drug or death, whichever occurs first (up to 34 months)

  5. Progression-free survival after initiating a next-line treatment (PFS2)

    Time from randomization until the progression event after initiating a next-line treatment or death due to any cause, whichever occurs first

    Time frame: From randomization until the next-line progression event or death due to any cause, up to 34 months

  6. Progression-free Survival (PFS) as assessed by a Blinded Independent Central Review (BICR), per RECIST v1.1

    Time frame: From randomization until disease progression (PD) or death, whichever occurs first (up to 34 months)

  7. EuroQol-5 Dimensions-5 Levels Quality of Life Questionnaire (EQ-5D-5L)

    EQ-5D-5L is a generic questionnaire that assesses health status as perceived by the patient across 5 categories (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) and overall.

    Time frame: From baseline and at specified timepoints up to 34 months

07

Study locations

185 sites

Showing the first 100 of 185 sites across 17 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Secord AA, Powell MA, McAlpine J. Molecular Characterization and Clinical Implications of Endometrial Cancer. Obstet Gynecol. 2025 Nov 1;146(5):660-671. doi: 10.1097/AOG.0000000000006080. Epub 2025 Sep 18. PubMed 40966692 ↗
  • Makker V, Perez-Fidalgo JA, Valabrega G, Hamilton E, Van Gorp T, Sehouli J, Reginacova K, Richardson DL, Perri T, Oza AM, Miller DS, Alia EMG, De Giorgi U, Henry S, Spitz DL, Wimberger P, Bednarikova M, Chon HS, Martinez-Garcia J, Pisano C, Berek JS, Romero I, Scambia G, Farinas-Madrid L, Buscema J, Schochter F, Li K, Kalyanapu P, Walker CJ, Vergote I. Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study. Gynecol Oncol. 2024 Jun;185:202-211. doi: 10.1016/j.ygyno.2024.05.016. Epub 2024 Jun 3. PubMed 38834399 ↗
  • Vergote I, Perez Fidalgo A, Valabrega G, Monk BJ, Herzog T, Cibula D, Colombo N, Pothuri B, Sehouli J, Korach J, Barlin J, Papadimitriou CA, van Gorp T, Richardson D, McCarthy M, Antill Y, Mirza MR, Li K, Kalyanapu P, Slomovitz B, Coleman RL. ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial design. Int J Gynecol Cancer. 2024 Aug 5;34(8):1283-1289. doi: 10.1136/ijgc-2024-005412. PubMed 38627035 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2023 to primary completion in May 2026, 37 months.

Of 44 phase 3 interventional studies under Endometrial Neoplasms, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 126. This study's 37 months is below that.

Primary completion moved once since we started tracking on Sep 25, 2026: Aug 2026 → May 2026, on Sep 30, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2022
First posted
Nov 10, 2022
StartActual
Apr 18, 2023
Primary completionActual
May 22, 2026was Aug 2026
CompletionEst.
Jan 2028
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
14 sites removed
Show 14 removed
  • Trials365, LLC · Shreveport, United States
  • University of Cincinnati Medical Center · Cincinnati, United States
  • Soon Chun Hyang University Hospital Cheonan · Cheonan, South Korea
  • Severance Hospital (Yonsei University Health System) · Seoul, South Korea
  • Samsung Changwon Hospital · Changwon, South Korea
  • National Cancer Center (NCC) · Goyang-si, South Korea
  • Seoul National University Bundang Hospital · Seoul, South Korea
  • Asan Medical Center · Seoul, South Korea
  • Memorial Hospital of South Bend · South Bend, United States
  • Our Lady of the Lake Hospital, Inc. · Baton Rouge, United States
  • Women's Cancer Center of Nevada · Las Vegas, United States
  • Tom Baker Cancer Centre · Calgary, Canada
  • IASO Hospital · Marousi, Greece
  • Taipei Veterans General Hospital · Taipei, Taiwan
across 2 updates, Sep 30, 2026 – Oct 29, 2026
Primary completion
Aug 2026→May 22, 2026 (actual)
Sep 30, 2026
Show all 2 updates
  1. Oct 29, 2026
    6 sites removed
    Show 6 removed
    • Memorial Hospital of South Bend · South Bend, United States
    • Our Lady of the Lake Hospital, Inc. · Baton Rouge, United States
    • Women's Cancer Center of Nevada · Las Vegas, United States
    • Tom Baker Cancer Centre · Calgary, Canada
    • IASO Hospital · Marousi, Greece
    • Taipei Veterans General Hospital · Taipei, Taiwan
    + 1 other change: verification date
  2. Sep 30, 2026
    8 sites removed
    Show 8 removed
    • Trials365, LLC · Shreveport, United States
    • University of Cincinnati Medical Center · Cincinnati, United States
    • Soon Chun Hyang University Hospital Cheonan · Cheonan, South Korea
    • Severance Hospital (Yonsei University Health System) · Seoul, South Korea
    • Samsung Changwon Hospital · Changwon, South Korea
    • National Cancer Center (NCC) · Goyang-si, South Korea
    • Seoul National University Bundang Hospital · Seoul, South Korea
    • Asan Medical Center · Seoul, South Korea
    Primary completion Aug 2026→May 22, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05611931
Collaborators
GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Belgian Gynaecological Oncology Group, North Eastern German Society of Gynaecological Oncology, The Central and Eastern European Gynecologic Oncology Group, Israeli Society of Gynecologic Oncology, Australia New Zealand Gynaecological Oncology Group, Multicenter Italian Trials in Ovarian Cancer (MITO), Grupo Español de Investigación en Cáncer de Ovario, Hellenic Cooperative Oncology Group, Cancer Trials Ireland (CTI), Mario Negri Gynecologic Oncology group (MaNGO)
Responsible party
Sponsor
First posted
Nov 10, 2022
Start date
Apr 18, 2023
Primary completion
May 22, 2026
Completion
Jan 2028 (estimated)
Last update
Oct 29, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Selinexor

Start the discussion